All Company Presentation submissions will be reviewed by the BIO Investor Forum Team.
Get the most out of the BIO Investor Forum by giving a 13-minute Company Presentation at the BIO Investor Forum.
Company Presentations allow you to share your R&D progress in front of an exclusive audience of investors and other biotech executives at the BIO Investor Forum – all eager to learn about future therapies for patients.
Please note that Companies that are approved to present must pay a Company Presentation fee in addition to being registered to attend the BIO Investor Forum.
As a presenting company, you'll benefit from enhanced brand visibility, including:
- A 13-minute presentation slot to showcase your company's pipeline, R&D activities, and future fundraising goals.
- Exposure on our website, event app, and printed presentation schedule for maximum reach.
- Ready-to-use social media graphics to promote your participation.
- A special tag in the BIO One-on-One Partnering™ system, highlighting your company to potential partners and investors.
Company Presentation Fees
These rates do not include registration (separate fee required - see below).
More information on how your company would be classified in registration.
Registration Fees
*All registrants are subject to approval.
**Partnering access is not included/provided with service provider registrations. To receive this benefit, please contact sponsor@bio.org for sponsorship opportunities.
Registration benefits are subject to change.
REGISTRATION CLASSIFICATIONS
REGISTRATION POLICIES
For the purposes of registration for any BIO event, conference or meeting, the classification of a registrant as a research and development company, an industry service provider, an academic & technology licensing officer or a qualifying investor is subject to review by BIO. In its sole discretion, BIO reserves the right to make the determination of the proper classification of a registrant. Depending on this classification, an additional registration fee may be required. BIO reserves the right to publish materials and restrict conference and/or partnering system access consistent with these determinations.